Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
12 02 2020
Historique:
entrez: 14 2 2020
pubmed: 14 2 2020
medline: 18 2 2021
Statut: epublish

Résumé

To formulate a decision analysis model based on recently published data that addresses the dilemma, whether improvement in quality of life rationalises continued proton pump inhibitors (PPI) use despite the risk of gastric cancer (GC) in patients with functional dyspepsia (FD). A Markov model consisting of an initial decision regarding treatment with PPI (denoting it by PPI strategy) or any other treatment without PPI (denoting it by placebo strategy) was designed. Data from prospective cross-sectional studies indicating risk stratification for GC after the use of PPI, combined with a Markov model that comprised the following states: Live, GC stages 1-4, Death. The primary outputs included quality-adjusted life years (QALYs) and life expectancy (LE). The improvement in utility in FD without PPI as compared with PPI use was tested (PPI vs placebo strategies). Sensitivity analyses were performed to evaluate the robustness of the model and address uncertainty in the estimation of model parameters. We considered only patients whose symptoms were relieved with PPIs and thus, had a better quality of life compared with patients who did not receive PPIs. The base case model showed that PPIs compared with placebo decreased LE by 58.4 days with a gain of 2.1 QALY. If utility (quality of life of patients with FD using PPI compared with patients with FD without PPI) improved by more than 0.8%, PPI use is considered better than placebo. Older patients benefited less from PPI treatment than did younger patients. To bridge the gap between evidence and decision making, we found that even a small improvement in the QALY justified continuing PPI treatment.

Identifiants

pubmed: 32051298
pii: bmjopen-2019-031091
doi: 10.1136/bmjopen-2019-031091
pmc: PMC7045183
doi:

Substances chimiques

Proton Pump Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e031091

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Otolaryngol Head Neck Surg. 2016 Oct;155(4):547-54
pubmed: 27188706
Gut. 2006 Nov;55(11):1538-44
pubmed: 16785284
Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):509-517
pubmed: 29195670
Am J Gastroenterol. 2017 Jul;112(7):988-1013
pubmed: 28631728
BMC Gastroenterol. 2013 Oct 01;13:145
pubmed: 24083350
Am J Med. 2009 Oct;122(10):896-903
pubmed: 19786155
Ann Oncol. 2012 Jan;23(1):28-36
pubmed: 21536659
Gastroenterology. 1994 Nov;107(5):1312-8
pubmed: 7926495
Cochrane Database Syst Rev. 2017 Mar 08;3:CD011194
pubmed: 28271513
Dig Dis. 2014;32(3):230-4
pubmed: 24732188
BMJ Open. 2017 Oct 30;7(10):e017739
pubmed: 29084798
Aliment Pharmacol Ther. 2014 May;39(9):984-91
pubmed: 24617286
Expert Opin Drug Saf. 2016 Jan;15(1):53-63
pubmed: 26560097
Eur J Clin Pharmacol. 2008 Oct;64(10):935-51
pubmed: 18679668
Med Decis Making. 1993 Oct-Dec;13(4):322-38
pubmed: 8246705
N Engl J Med. 1995 Oct 26;333(17):1106-10
pubmed: 7565948
Am J Transl Res. 2018 Jan 15;10(1):292-303
pubmed: 29423014
QJM. 2019 Nov 1;112(11):835-840
pubmed: 31251364
JAMA Intern Med. 2016 Feb;176(2):238-46
pubmed: 26752337
Arthritis Res Ther. 2013;15 Suppl 3:S5
pubmed: 24267413
Cochrane Database Syst Rev. 2017 Mar 16;3:CD011969
pubmed: 28301676
BMC Gastroenterol. 2011 May 11;11:52
pubmed: 21569313
Lancet. 2008 Oct 4;372(9645):1198-200
pubmed: 19094939
BMC Med. 2016 Nov 9;14(1):179
pubmed: 27825371
Ann Intern Med. 2014 Dec 2;161(11):812-8
pubmed: 25437409
Gut. 2002 Oct;51(4):502-6
pubmed: 12235071
Gut. 2012 Sep;61(9):1261-8
pubmed: 22174193
Gut. 2018 Jan;67(1):28-35
pubmed: 29089382
Br J Cancer. 2009 May 5;100(9):1503-7
pubmed: 19352380
Ther Adv Chronic Dis. 2018 Jan;9(1):23-32
pubmed: 29344328
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1706-1719.e5
pubmed: 27211501
Gut. 2003 Jul;52(7):942-6
pubmed: 12801948
Nephrol Dial Transplant. 2018 Feb 1;33(2):331-342
pubmed: 28339835

Auteurs

Efrat Broide (E)

The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Shamir Medical Center (Assaf Harofeh Medical), Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Adi Eindor-Abarbanel (A)

The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Shamir Medical Center (Assaf Harofeh Medical), Zerifin, Israel adiabarbanel@gmail.com.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Haim Shirin (H)

The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Shamir Medical Center (Assaf Harofeh Medical), Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Vered Richter (V)

The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Shamir Medical Center (Assaf Harofeh Medical), Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shay Matalon (S)

The Kamila Gonczarowski Institute of Gastroenterology and Liver Diseases, Shamir Medical Center (Assaf Harofeh Medical), Zerifin, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Moshe Leshno (M)

Coller School of Management, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH